Nov 06, 2024
Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
Sep 16, 2024
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
Sep 09, 2024
Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
Sep 04, 2024
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
Aug 21, 2024
Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
Jul 17, 2024
Jazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
Jun 20, 2024
Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
Jun 01, 2024
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
May 30, 2024
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
May 29, 2024
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
May 29, 2024
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
May 22, 2024
Jazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism
May 01, 2024
Jazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
Apr 17, 2024
Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
Apr 10, 2024
Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
Apr 02, 2024
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
Mar 12, 2024
Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
Feb 28, 2024
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
Feb 27, 2024
Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors
Feb 21, 2024
Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer